25 Jul 2024
In the current phase of our project, named the discovery phase, the JaxBio and Tel Aviv University (TAU) teams have been diligently working towards identifying sets of biomarkers that can distinguish between nine types of hematological malignancies and pre-malignant conditions from healthy controls. Over 600 patients have been recruited for this effort as part of a clinical trial conducted in four medical centres across Europe.
JaxBio has developed a unique technology to detect disease-specific biomarkers in the blood, with a high sensitivity. The Tel Aviv University (TAU) team has concentrated on processing and analysing genomic DNA samples, while JaxBio has focused on cell-free DNA extracted from the blood. Together, JaxBio and TAU teams have successfully identified disease-specific methylation biomarker panels, demonstrating an accuracy of over 90% in disease classification. As the discovery phase nears completion, the teams are using an AI algorithm to finalise and optimise these biomarker panels.
In the next step, these optimised panels will be printed onto a targeted chip, the HemaChip, which aims to offer a simple, robust, and low-cost solution for cancer diagnosis. Concurrently, we are actively engaged in the design of the HemaChip, aiming to have it ready for distribution to medical centres in the near future.
